Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SARS-CoV-2 vaccination immunogenicity study in older adults from the Doetinchem Cohort
NL-OMON54152Phase 4Completed
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Mar 2021
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of SARS-CoV-2 vaccine in coronavirus disease 2019 (COVID-19), sponsored by National Institute for Public Health and the Environment. Primary endpoints: Spike-specific antibody levels, Functional T-cell responses and 1 more. Started Mar 2021; status: completed.
02
Drugs
SARS-CoV-2 vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON54152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54152.